Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Myasthenia Gravis 5Neoplasms, Plasma Cell 3Neoplasms 3Multiple Myeloma 2Lymphoma 2Leukemia 2Infections 2Hematologic Neoplasms 2Urologic Neoplasms 1Neuromyelitis Optica 1Neuroblastoma 1Myelitis, Transverse 1Melanoma 1Lymphoma, Non-Hodgkin 1Limbic Encephalitis 1Immunoglobulin Light-chain Amyloidosis 1Epilepsy 1Epilepsies, Partial 1Drug Resistant Epilepsy 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Autoimmune Diseases of the Nervous System 1Autoimmune Diseases 1

Interventions

Sirolimus 4LY3295668 erbumine 3Everolimus 3Medical Marijuana 2Anticonvulsants 2ziprasidone 1perampanel 1enzalutamide 1clevidipine 1brivaracetam 1Zolpidem 1Warfarin 1Vigabatrin 1Vecuronium Bromide 1Vancomycin 1Tranexamic Acid 1Topotecan 1Tobramycin 1Therapeutic Touch 1Temozolomide 1TAS-119 1Surgical Procedures, Operative 1Sulfasalazine 1Spironolactone 1Sevoflurane 1Sevelamer 1Saline Solution 1Rocuronium 1Registries 1Radiotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Epilepsy × Immunoglobulins, Intravenous × Clear all
NCT01545518 2014-09-01

IVIG Treatment for Refractory Immune-Related Adult Epilepsy

Emory University

Phase 2 Terminated
20 enrolled 3 charts

Drug Resistant Epilepsy, Autoimmune Diseases, Epilepsy, Epilepsies, Partial, Autoimmune Diseases of the Nervous System, Limbic Encephalitis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡